Chemistry/Immunology Reagents/Analyzer
openDEFENSE HEALTH AGENCY HCD WEST · DEPT OF DEFENSE
Description
Notice of Intent to Sole Source HT941027N0014 THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE PURCHASE ORDER CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – San Diego (HCD-SD), Echo Branch intends to award a firm fixed price five (5)-Year Purchase order RFO 12.102 (b) for acquisitions valued over the SAT, only one source being available to meet the Government’s needs, to: ORTHO CLINICAL DIAGNOSTICS SINGAPORE PTE LTD, KOREA BRANCH 366 HANGANG-DAERO YONGSAN-GU, SEOUL, 04323 SOUTH KOREA UEI: JNSJRDQQH2J6 CAGE: 767DF The North American Industry Classification System (NAICS) code for this requirement is 325413 - Pharmaceutical Preparation Manufacturing; the business size standard is 1,250 (in number of employees). The Product Service Code (PSC) is 6550 – Invitro Diagnostics Substances Reagents The objective of this sole source award is to procure Chemistry/Immunology Reagents with Analyzer for Brian D. Allgood Army Community Hospital, South Korea for the Department of Pathology. The contractor-furnished chemistry and immunology analyzers shall be capable of providing complete chemistry and immunochemistry testing. The entire analyzer system shall be serviced and supplied through a single Contractor awarded the contract, including all parts, equipment, and supplies not manufactured, provided, or serviced directly by the Contractor. The system shall provide redundancy to ensure continuous operations. Each analyzer shall have the capacity to perform both chemistry and immunology assays. The Contractor shall provide the system, training, supplies, reagents, unscheduled maintenance, and preventive maintenance. All equipment displays and supporting literature shall be in English. The Contractor shall include delivery, installation, all calibrators and standards, reagents and reagent packs, and quality-control materials necessary to perform the specified assays. The Contractor shall also perform initial method validations in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. The Contractor shall remove the analyzers upon contract termination. Rationale Justifying: Ortho Clinical Diagnostics Singapore Pte. Ltd., Korea Branch, a division of QuidelOrtho Corporation, is the sole manufacturer capable of providing clinical chemistry and integrated chemistry/immunoassay analyzers that meet the Government’s test-volume requirements without requiring a facility water supply. The Defense Health Agency requires analyzers that use 100 percent waterless, dry-slide technology. These sites cannot receive reagent-grade water into the facility for safe, quality laboratory testing and are not approved by the state to discharge biohazardous waste into any drain. This technology is unique to QuidelOrtho’s VITROS® line of analyzers and is essential to meeting the agency’s operational and mission requirements for the following reasons: Infrastructure Independence: VITROS dry-slide technology eliminates the need for water, plumbing, and drains. This is a critical advantage in military healthcare environments, where logistical footprints must be minimized. It ensures operational continuity and significantly reduces infrastructure dependencies. Enhanced Quality and Reliability: The system uses disposable tips for each sample, eliminating the risk of sample-to-sample carryover and reagent-to-reagent contamination that can occur in traditional wet-chemistry systems. This supports the accuracy and reliability of test results for patient care, particularly for high-acuity, time-sensitive assays. For example, emergency physicians rely on rapid, accurate first-run results for high-sensitivity troponin to triage potential heart attacks; procalcitonin and lactic acid to diagnose life-threatening sepsis; and potassium levels to treat sudden acute renal or metabolic failure. In these life-threatening situations, a false or contaminated initial result can delay critical medical intervention. The dry-slide technology’s elimination of sample carryover helps ensure that providers can rely on the initial result when time is of the essence. Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides calibration stability of up to six months for most assays. This extended calibration interval substantially reduces the time and labor associated with daily calibration and quality-control procedures while also reducing reagent waste.systems. This ensures the highest accuracy and reliability of test results for patient care, which is absolutely critical for high-acuity, time-sensitive assays. For example, emergency physicians rely on rapid, flawless first-time results for high sensitivity troponin to triage imminent heart attacks, procalcitonin and lactic acid to diagnose life-threatening sepsis, and potassium levels to treat sudden acute renal or metabolic failure. In these life-or-death scenarios, a false or contaminated first read delays vital medical interventions; the dry-slide technology's elimination of sample carryover ensures providers can trust the initial result when time is of the essence. Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides up to a six-month calibration stability for most assays. This extended frequency drastically reduces the time and labor spent on daily calibration and quality control procedures while decreasing reagent waste. Product List: Chemistry/Immunology Annual Test Count Test Base Year 6-Month Option Year I Option Year II Option Year III Option Year IV 1 ACETAMINOPHEN 1,541 1,731 1,783 1,836 1,891 2 ALBUMIN 9,202 17,513 18,038 18,579 19,136 3 ALANINE AMINOTRANSFERASE 9,209 17,529 18,055 18,597 19,155 4 ALKALINE PHOSPHATASE 9,285 17,684 18,215 18,762 19,325 5 AMYLASE 1,470 1,586 1,634 1,683 1,734 6 ASPARTATE AMINOTRANSFERASE 9,914 18,980 19,549 20,136 20,740 7 BILIRUBIN TOTAL 9,581 18,295 18,844 19,409 19,991 8 BILIRUBIN DIRECT 1,343 2,088 2,151 2,216 2,283 9 BILIRUBIN CONJUGATED 662 1,003 1,033 1,064 1,096 10 BILIRUBIN UNCONJUGATED 662 1,003 1,033 1,064 1,096 11 BILIRUBIN NEONATAL 85 132 136 140 144 12 CALCIUM 9,642 18,420 18,973 19,542 20,128 13 CARBON DIOXIDE 9,626 18,387 18,939 19,507 20,092 14 CHLORIDE 9,771 18,686 19,247 19,824 20,419 15 CHOLESTEROL TOTAL 4,951 8,757 9,020 9,291 9,570 16 CK-MB 1,992 2,660 2,740 2,822 2,907 17 C-REACTIVE PROTEIN 2,349 3,396 3,498 3,603 3,711 18 CREATININE 10,084 19,360 19,941 20,539 21,155 19 CREATININE, RANDOM URINE 206 396 408 420 433 20 CREATINE KINASE 1,993 2,663 2,743 2,825 2,910 21 ETHANOL 2,674 4,065 4,187 4,313 4,442 22 G-GLUTAMYL TRANSFERASE 2,195 3,079 3,171 3,266 3,364 23 GENTAMICIN PEAK 834 579 596 614 632 24 GENTAMICIN TROUGH 222 154 159 164 169 25 GLUCOSE 10,228 19,784 20,378 20,989 21,619 26 GLUCOSE 1ST 46 89 92 95 98 27 GLUCOSE 2ND 46 89 92 95 98 28 GLUCOSE 3RD 46 89 92 95 98 29 GLUCOSE POSTPRANDIAL 3 4 4 4 4 30 GLUCOSE POST 50G GLUCOLA 1H 149 288 297 306 315 31 GLUCOSE POST 75G GLUCOLA 2H 12 23 24 25 26 32 GLUCOSE FASTING 918 1,775 1,828 1,883 1,940 33 GLUCOSE CSF 23 44 45 46 47 34 HDL CHOLESTEROL 4,879 8,609 8,867 9,133 9,407 35 IRON 1,465 1,575 1,622 1,671 1,721 36 LACTATE 1,647 1,951 2,010 2,070 2,132 37 LACTATE DEHYDROGENASE 1,476 1,598 1,646 1,695 1,746 38 LIPASE 2,637 3,990 4,110 4,233 4,360 39 MAGNESIUM 2,103 2,889 2,976 3,065 3,157 40 PHOSPHORUS 1,823 2,312 2,381 2,452 2,526 41 POTASSIUM 10,047 19,254 19,832 20,427 21,040 42 PROTEIN 9,075 17,253 17,771 18,304 18,853 43 PROTEIN CSF 847 303 312 321 331 44 PROTEIN, RANDOM URINE 1,184 996 1,026 1,057 1,089 45 SALICYLATES 1,520 1,689 1,740 1,792 1,846 46 SODIUM 10,568 20,327 20,937 21,565 22,212 47 TRIGLYCERIDE 4,983 8,822 9,087 9,360 9,641 48 UREA NITROGEN 9,808 18,761 19,324 19,904 20,501 49 URIC ACID 1,556 1,762 1,815 1,870 1,926 50 VANCOMYCIN PEAK 574 446 459 473 487 51 VANCOMYCIN TROUGH 551 429 442 455 469 52 HCG QN 2,628 3,972 4,091 4,214 4,340 53 THYROTROPIN 5,327 9,531 9,817 10,112 10,415 54 T4 FREE 2,318 3,332 3,432 3,535 3,641 55 THYROXINE, TOTAL 1,950 2,575 2,652 2,732 2,814 56 TROPONIN I CARDIAC 2,855 4,438 4,571 4,708 4,849 57 HEPATITIS B SURFACE AG 3,435 5,633 5,802 5,976 6,155 58 HEPATITIS B SURFACE AB 3,848 6,485 6,680 6,880 7,086 59 HEPATITIS B CORE AB TOTAL 3,522 5,183 5,339 5,500 5,665 60 HEPATITIS C AB 3,193 5,136 5,290 5,449 5,613 61 HEPATITIS A IGM 2,675 4,068 4,190 4,316 4,446 62 HEPATITIS A AB, TOTAL 2,964 4,663 4,803 4,947 5,095 63 RUBELLA VIRUS IGG 1,724 2,108 2,171 2,236 2,303 64 HBA1C-IFCC, NGSP 4,668 8,173 8,418 8,671 8,931 65 PRO-BNP 2,322 3,341 3,441 3,544 3,650 Agency and Requirement Description and Market Research Conducted: DHA HCD-SD is supporting Brian D. Allgood Army Community Hospital in South Korea, with a requirement for Chemistry/Immunology Reagents with Analyzer. Specifically, this requirement is for tests in the product list above. Extensive market research through the General Services Administration (GSA), Federal Supply Schedules (FSS), or other mandatory sources. Broad database searches were conducted across FPDS-NG, GSA Advantage, GSA eLibrary, GSA Global Supply, NASA SEWP, and VA FSS using keywords such as “Chemistry”. These searches either yielded zero results or failed to identify contractors capable of providing the exact or equal supplies required. Additionally, a review of internal contracting activity via the BPA Tracker revealed no similar contracts currently in place to leverage. Open market research, including internet searches and personal telephone contacts with potential vendors, confirmed that while "Chemistry/Immunology Reagents/Analyzers" are commercially available RFO 12.102(b) only Ortho Clinical Diagnostics Singapore PTE LTD, Korea Branch is the only vendor that can meet the agency's requirements. Delivery location: BRIAN D. ALLGOOD ARMY COMMUNITY HOSPITAL 348TH QM CO SRA BLDG 1603 CAMP HUMPHREYS PYEONGTAEK, 17982 Estimated Delivery Schedule: 1 April 2027 to 30 September 2031 (Including a 6 month base period and four (4) 12 month option years). Based on market research and previous acquisition history, it has been determined that Ortho Clinical Diagnostics Singapore PTE LTD, Korea Branch, is the only source that can meet the Government’s minimum requirements to provide chemistry/immunology reagents and analyzer for the Brian D. Allgood Army Community Hospital. This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the chemistry/immunology reagents and analyzer for the Brian D. Allgood Army Community Hospital. Capability statements shall not exceed two (2) (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order. If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Contract Specialist Susan Fujita at susan.m.fujita.civ@health.mil and Contracting Officer Cha-on P. Gordon at cha-on.p.gordon2.civ@health.mil. The closing date for challenges is no later than 11:00 a.m. (Hawaii Time), Thursday December 3, 2026. NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
Key facts
- Reference
- HT941027N0014
- Procedure
- Special Notice
- Contact
- Susan Fujitasusan.m.fujita.civ@health.mil8084339506
What a subscription adds to this notice
- The documents — every attachment, with its text extracted and searchable
- Qualification — the notice scored against your company profile
- Tracking and alerts — a pipeline for your bids, and the matching notices by email
- Calendar export — the deadline as a calendar file
- The API and MCP — the same record in your own tools and your AI assistant
Provenance
- Source
- sam-gov
- Notice id
- bf19497f9cfc4dc4855e9bbc6a1848ae
- First seen
- 22 Nov 2026
- Last updated
- 22 Nov 2026
Licence US Government work — public domain (17 U.S.C. § 105) ↗
Source: SAM.gov, U.S. General Services Administration — a U.S. Government work, not subject to copyright in the United States.
GET /api/v1/tenders/d5df6265-e5a8-4d73-a838-479fe4f23e98The source notice is authoritative — verify deadlines and documents there before bidding.